{"id":"pyrazinamide-z","safety":{"commonSideEffects":[{"rate":"null","effect":"Hyperuricemia"},{"rate":"null","effect":"Gout"},{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Arthralgias"}]},"_chembl":{"chemblId":"CHEMBL614","moleculeType":"Small molecule","molecularWeight":"123.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pyrazinamide is a prodrug that requires activation by the bacterial enzyme pyrazinamidase to form pyrazinoic acid. Once activated, pyrazinoic acid accumulates in the mycobacterial cell and inhibits the enzyme pantothenate synthetase, disrupting the synthesis of coenzyme A and ultimately impairing bacterial energy production and nucleic acid synthesis. This mechanism is particularly effective against intracellular and slowly replicating tubercle bacilli.","oneSentence":"Pyrazinamide is converted to pyrazinoic acid inside Mycobacterium tuberculosis cells, where it disrupts bacterial energy metabolism and nucleic acid synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:44.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy"}]},"trialDetails":[{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT03057756","phase":"","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2015-09-11","conditions":"Multi-drug Resistant Tuberculosis","enrollment":23},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07163143","phase":"PHASE3","title":"Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2025-11","conditions":"Tuberculosis (TB)","enrollment":784},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT07058090","phase":"PHASE1","title":"Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi","status":"NOT_YET_RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07","conditions":"Drug Induced Liver Injury, Tuberculosis (TB)","enrollment":410},{"nctId":"NCT04260477","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimen","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-03-01","conditions":"Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":370},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06727864","phase":"PHASE3","title":"Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial","status":"RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2024-01-01","conditions":"Pulmonary Tuberculosis","enrollment":270},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":"Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis","enrollment":309},{"nctId":"NCT04179500","phase":"PHASE2","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2021-09-16","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":26},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT04176250","phase":"PHASE2","title":"Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2020-01-16","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT03830671","phase":"PHASE4","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2019-03-08","conditions":"Multi-drug Resistant Tuberculosis","enrollment":515},{"nctId":"NCT02554318","phase":"NA","title":"Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2013-11","conditions":"Pulmonary Tuberculosis, Body Weight Changes, Motor Activity","enrollment":147},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT02958709","phase":"PHASE1, PHASE2","title":"Optimizing Treatment to Improve TBM Outcomes in Children","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-22","conditions":"Tuberculosis, Meningeal","enrollment":38},{"nctId":"NCT04766307","phase":"PHASE4","title":"A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2016-07-20","conditions":"Tuberculosis, Pulmonary","enrollment":1100},{"nctId":"NCT02231229","phase":"PHASE4","title":"Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-07-23","conditions":"Tuberculosis","enrollment":204},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT00933790","phase":"PHASE3","title":"Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2009-09-14","conditions":"HIV Infection, Pulmonary TB","enrollment":331},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT02457208","phase":"PHASE1","title":"PK Study of Anti-TB Drugs","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-07-07","conditions":"Tuberculosis","enrollment":61},{"nctId":"NCT01498419","phase":"PHASE2","title":"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-03","conditions":"Pulmonary Tuberculosis","enrollment":207},{"nctId":"NCT01215851","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-10","conditions":"Pulmonary Tuberculosis","enrollment":85},{"nctId":"NCT01691534","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-10","conditions":"Pulmonary Tuberculosis","enrollment":105},{"nctId":"NCT02313610","phase":"PHASE2","title":"Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-04","conditions":"Pulmonary Tuberculosis","enrollment":253},{"nctId":"NCT01225640","phase":"PHASE2","title":"PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay","status":"COMPLETED","sponsor":"Sequella, Inc.","startDate":"2011-08","conditions":"Tuberculosis","enrollment":59},{"nctId":"NCT02496572","phase":"","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-09","conditions":"Multidrug Resistant Tuberculosis","enrollment":110},{"nctId":"NCT01222338","phase":"PHASE2","title":"Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients","status":"COMPLETED","sponsor":"Lisichansk Regional Tuberculosis Dispensary","startDate":"2010-01","conditions":"Tuberculosis","enrollment":123},{"nctId":"NCT00495326","phase":"PHASE2, PHASE3","title":"Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-12","conditions":"Tuberculosis, Aids, Hiv Infections","enrollment":570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pyrazinamide (Z)","genericName":"Pyrazinamide (Z)","companyName":"Global Alliance for TB Drug Development","companyId":"global-alliance-for-tb-drug-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyrazinamide is converted to pyrazinoic acid inside Mycobacterium tuberculosis cells, where it disrupts bacterial energy metabolism and nucleic acid synthesis. Used for Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}